Adarsh Joshi

969 total citations
19 papers, 633 citations indexed

About

Adarsh Joshi is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Immunology. According to data from OpenAlex, Adarsh Joshi has authored 19 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 5 papers in Immunology. Recurrent topics in Adarsh Joshi's work include Multiple Myeloma Research and Treatments (3 papers), Hepatitis B Virus Studies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Adarsh Joshi is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Hepatitis B Virus Studies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Adarsh Joshi collaborates with scholars based in United States, United Kingdom and Canada. Adarsh Joshi's co-authors include Rebecca R. Hozak, Jonathan D. Schwartz, Yihuan Xu, Philip Abraham, Aabha Nagral, Shobna Bhatia, Anuj Gaggar, Audrey Lau, Edward Gane and Harry L.A. Janssen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Adarsh Joshi

18 papers receiving 622 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adarsh Joshi United States 10 251 196 188 170 141 19 633
Chao-Jung Tsao Taiwan 11 411 1.6× 307 1.6× 153 0.8× 195 1.1× 157 1.1× 22 783
Latasha Little United States 10 240 1.0× 169 0.9× 221 1.2× 115 0.7× 36 0.3× 27 662
Yabing Cao China 15 182 0.7× 189 1.0× 191 1.0× 350 2.1× 87 0.6× 52 811
Alícia Domingo Spain 13 131 0.5× 138 0.7× 289 1.5× 209 1.2× 171 1.2× 24 712
Jennifer Ma United States 14 122 0.5× 121 0.6× 253 1.3× 321 1.9× 159 1.1× 54 817
Antonio Cubillo Gracián Spain 15 308 1.2× 125 0.6× 108 0.6× 439 2.6× 119 0.8× 30 697
Yuji Eso Japan 17 382 1.5× 259 1.3× 150 0.8× 292 1.7× 117 0.8× 52 806
Ayse U. Akarca United Kingdom 14 87 0.3× 92 0.5× 183 1.0× 475 2.8× 196 1.4× 34 773
Huanling Zhu China 12 71 0.3× 132 0.7× 194 1.0× 138 0.8× 90 0.6× 48 613

Countries citing papers authored by Adarsh Joshi

Since Specialization
Citations

This map shows the geographic impact of Adarsh Joshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adarsh Joshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adarsh Joshi more than expected).

Fields of papers citing papers by Adarsh Joshi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adarsh Joshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adarsh Joshi. The network helps show where Adarsh Joshi may publish in the future.

Co-authorship network of co-authors of Adarsh Joshi

This figure shows the co-authorship network connecting the top 25 collaborators of Adarsh Joshi. A scholar is included among the top collaborators of Adarsh Joshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adarsh Joshi. Adarsh Joshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
3.
Vincent, Sylvie, Zhenqiang Su, Veronica Bunn, et al.. (2022). Molecular analysis of circulating tumor DNA (ctDNA) in patients (pts) with EGFR exon 20 insertion-positive (ex20ins+) advanced NSCLC treated with mobocertinib.. Journal of Clinical Oncology. 40(16_suppl). 9108–9108. 2 indexed citations
4.
Vincent, Sylvie, Zhenqiang Su, Adarsh Joshi, Kalyani Penta, & Pingkuan Zhang. (2022). Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib. Cancer Research. 82(12_Supplement). 2781–2781. 2 indexed citations
5.
6.
Lutz, Justin D., Audrey Lau, Anuj Gaggar, et al.. (2019). Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects. Antiviral Therapy. 25(3). 171–180. 12 indexed citations
7.
Gane, Edward, Hyung Joon Kim, Kumar Visvanathan, et al.. (2018). Safety, Pharmacokinetics and Pharmacodynamics of Oral TLR8 Agonist GS-9688 in Patients with Chronic Hepatitis B: A Randomized, Placebo-Controlled, Double-Blind Phase 1b Study. Hepatology. 68. 2 indexed citations
8.
Janssen, Harry L.A., Maurizia Rossana Brunetto, Yoon Jun Kim, et al.. (2017). Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. Journal of Hepatology. 68(3). 431–440. 142 indexed citations
9.
Joshi, Adarsh, Jenny Zhang, & Fang Ting Liang. (2017). Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study. Contemporary Clinical Trials. 63. 19–29. 3 indexed citations
10.
Barr, Paul M., Gene Saylors, Stephen E. Spurgeon, et al.. (2016). Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 127(20). 2411–2415. 114 indexed citations
11.
12.
Gupta, Vikas, Ruben A. Mesa, Michael W. Deininger, et al.. (2015). Circulating Cytokines and Markers of Iron Metabolism in Myelofibrosis Patients Treated with Momelotininb: Correlatives from the Ym-387-II Study. Blood. 126(23). 1600–1600. 1 indexed citations
13.
Camidge, D. Ross, Eamon M. Berge, Robert C. Doebele, et al.. (2014). A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(10). 1532–1539. 41 indexed citations
14.
García, Jorge A., Gary R. Hudes, Toni K. Choueiri, et al.. (2014). A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer. 120(11). 1647–1655. 26 indexed citations
15.
Penson, Richard T., Kathleen N. Moore, Gini F. Fleming, et al.. (2014). A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecologic Oncology. 134(3). 478–485. 26 indexed citations
16.
Zhu, Andrew X., Richard S. Finn, Mary F. Mulcahy, et al.. (2013). A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clinical Cancer Research. 19(23). 6614–6623. 122 indexed citations
17.
Holzer, Timothy R., Angie D. Fulford, Rebecca R. Hozak, et al.. (2013). Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung. PLoS ONE. 8(11). e80292–e80292. 39 indexed citations
18.
Joshi, Adarsh, et al.. (2002). Effect of N, P and pinching on the nutrient composition and uptake by African marigold.. 334–335. 4 indexed citations
19.
Nagral, Aabha, et al.. (1993). Congestive jejunopathy in portal hypertension.. Gut. 34(5). 694–697. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chao-Jung Tsao Breakdown of academic impact, for papers by Latasha Little Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by Alícia Domingo Breakdown of academic impact, for papers by Jennifer Ma Breakdown of academic impact, for papers by Antonio Cubillo Gracián Breakdown of academic impact, for papers by Yuji Eso Breakdown of academic impact, for papers by Ayse U. Akarca Breakdown of academic impact, for papers by Huanling Zhu
Rankless by CCL
2026